000			02387na a2200265 4500
999			_c1513 _d1513
003			PC1513
005			20210625062756.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aMartinez-Flores, Jose A. _92597 _eInstituto de Investigación i+12
100			_aMora Diaz, Sergio _91986 _eInmunología
100			_aMorales Cerdán, José María _9576 _eNefrología
100			_aPaz Artal, Estela _91510 _eInmunología
100			_aSerrano Hernández, Antonio _9661 _eInmunología
100			_aSerrano, Manuel _92598 _eInstituto de Investigación i+12
100			_aAlfaro, Javier _92596 _eInmunología
245	0	0	_aHeterogeneity between Diagnostic Tests for IgA anti-Beta2 Glycoprotein I: Explaining the Controversy in Studies of Association with Vascular Pathology. _h[artículo]
260			_bAnalytical Chemistry, _c2013
300			_a85(24):12093-8.
500			_aFormato Vancouver: Martínez-Flores JA, Serrano M, Alfaro J, Mora S, Paz-Artal E, Morales JM et al. Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology. Anal Chem. 2013 Dec 17;85(24):12093-8.
501			_aPMID: 24245938
504			_aContiene 34 referencias
520			_aIgA antibeta 2 Glycoprotein I (beta 2GPI) antibodies test can identify some patients with antiphospholipid syndrome (APS) that are negative for other isotypes. Controversy exists because some studies have reported a strong association of these antibodies with vascular disease, while others have not confirmed this observation. Our hypothesis is that these contradictory results may be due to differences among commercial diagnostic kits. To answer this question, we have compared the results obtained with several of the most commonly used commercial IgA anti beta 2GPI antibodies (a beta 2GPI) diagnostic assays on specimens from individuals suspected of having APS. Sera from 69 patients (37 positive and 32 negative for IgA a beta 2GPI) were analyzed, with seven different commercial ELISA kits for IgA a beta 2GPI, following instructions and cutoffs provided by the manufacturer. Our results showed important differences in the sensitivity and specificity of the different assays. Two of the seven kits tested had a sensitivity level below 65% for IgA a beta 2GPI, and three showed levels of specificity lower than 80%. Some commercial kits to detect IgA a beta 2GPI are suboptimal. Variability between kits may account for the discrepancy in results obtained and for the lack of consensus concerning their clinical significance. It is important that the scientific community work to standardize assay performance so that the true clinical significance of this important clinical marker can be clearly established.
710			_9395 _aServicio de Inmunología
710			_986 _aServicio de Nefrología
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1513.pdf _ySolicitar documento
942			_n0 _2ddc _cART